Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in Children and Adolescents With Episodic Migraine (OASIS PEDIATRIC [EM])
NCT03836040Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jul 2019
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of erenumab in episodic migraine, sponsored by Amgen. Started Jul 2019; status: active, not recruiting.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03836040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836040.